At the National Congress of Audiology (SIAF) in November 2023, Tinnitech disclosed new CLINICAL DATA that complement the 3-month psycho-physical improvement results disclosed in June at the SIO National Congress on the 55 patients of the 2022-23 trial, carried out by the Tor Vergata University Hospital in Rome, a center of excellence in Italian otolaryngology led by Professor Di Girolamo.
We concentrate the results shown here on the levels of THI (Tinnitus Handicap Index), the main international method of evaluating tinnitus, which measures the intensity of the disorder from 0 to 100.
Excellent clinical results
at 3 and 12 months
For the sake of brevity, we focused the results on the THI (Tinnitus Handicap Index), the main method of evaluating tinnitus in the world, which measures the severity of the disorder from 0 to 100.
Results after 3 months:
end of clinical protocol (May 2023)
- THI improved in 66% (2 out of 3 “improved” patients)*
- THI with an average value improved by 24% 42% (42% among 66% “positive”)
- THI improved “down from 10 to 0” in 1 out of 4 patients
- THI improved to “down from 10 to 0” in 4 out of 10 patients among the 66% improved
Results after 12 months
following and of treatment
- THI improved in 52% and remained stable 18% of patients (7 out of 10)
- THI with average value improved to the extent of 21,6%
- THI improved “down from 10 to 0” in 3 out of 4 patients
- THI improved to “down from 10 to 0” in n 4 out of 5 patients among the 66% improved
Qualifying details:
- The THI is defined as “slight” in the minimum evaluation range, from 16 to zero; from 10 to zero it is further reduced to “very slight or absent”.
- The period: results were achieved after a protocol of only 8 active weeks + intervals. We emphasise the effectiveness of these results despite a very short period in order to optimise the treatment of a complex and insidious pathology such as tinnitus.
- Official protocol without adaptations or customization: in order to ensure the consistency and reliability of our biostatistical data, we avoided using Acufree’s multiple acoustic and therapeutic adaptations which would normally enhance the prospects of improvement.
